Literature DB >> 8535413

Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020).

S Nochi1, N Asakawa, T Sato.   

Abstract

E2020 (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride) is currently being developed as a treatment for senile dementia of the Alzheimer type. Its mechanism of action is to increase central cholinergic activity by inhibiting acetylcholinesterase (AChE) in the brain. In this study, the kinetics of the inhibitory action of E2020 on AChE was examined in comparison with its derivatives (2A1050 and 2A1034) and the reference compound tetrahydroaminoacridine (THA) all of which have a similar action. Analysis of the data using Lineweaver-Burk plots shows that inhibition by the test compounds fell into the category of mixed type. Inhibitor dissociation constants for the free enzyme (KI) and acetyl-enzyme (KI) of E2020 are one or two orders of magnitude lower than those of 2A1050, 2A1034 and THA. These findings indicate the strong inhibitory effect of E2020 on AChE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8535413     DOI: 10.1248/bpb.18.1145

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  20 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.

Authors:  Jana R Cooke; Jose S Loredo; Lianqi Liu; Matthew Marler; Jody Corey-Bloom; Lavinia Fiorentino; Tamara Harrison; Sonia Ancoli-Israel
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 4.  Donepezil: a review of its use in Alzheimer's disease.

Authors:  M Dooley; H M Lamb
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

Review 5.  Donepezil.

Authors:  H M Bryson; P Benfield
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

6.  Chiral Separation, X-ray Structure, and Biological Evaluation of a Potent and Reversible Dual Binding Site AChE Inhibitor.

Authors:  Marco Catto; Leonardo Pisani; Eugenio de la Mora; Benny Danilo Belviso; Giuseppe Felice Mangiatordi; Andrea Pinto; Annalisa De Palma; Nunzio Denora; Rocco Caliandro; Jacques-Philippe Colletier; Israel Silman; Orazio Nicolotti; Cosimo Damiano Altomare
Journal:  ACS Med Chem Lett       Date:  2020-02-07       Impact factor: 4.345

7.  Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples.

Authors:  Tatsuya Kikuchi; Toshimitsu Okamura; Takuya Arai; Takayuki Obata; Kiyoshi Fukushi; Toshiaki Irie; Tetsuya Shiraishi
Journal:  Br J Pharmacol       Date:  2010-04       Impact factor: 8.739

Review 8.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

9.  Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses.

Authors:  P J Tiseo; C A Perdomo; L T Friedhoff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

10.  Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses.

Authors:  P J Tiseo; C A Perdomo; L T Friedhoff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.